Julie Fitzgerald to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Julie Fitzgerald has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.297
-
Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. J Clin Oncol. 2021 03 10; 39(8):920-930.
Score: 0.127
-
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Crit Care Med. 2017 Feb; 45(2):e124-e131.
Score: 0.097
-
Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome. Pediatr Blood Cancer. 2020 11; 67(11):e28693.
Score: 0.031
-
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 2016 06; 6(6):664-79.
Score: 0.023
-
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013 Jun 27; 121(26):5154-7.
Score: 0.019